PYRAMID注册研究中阿达木单抗治疗克罗恩病患者长达6年随访的淋巴瘤风险与总体安全性
PYRAMID注册研究前瞻性随访5025例中重度活动性克罗恩病患者长达6年,评估阿达木单抗安全性;观察到的淋巴瘤发生率为0.060事件/100人年,低于估算背景率0.084事件/100人年,单侧95%CI上限0.102事件/100人年低于背景率两倍0.168事件/100人年,达到排除淋巴瘤风险加倍的主要目标。
要点
- 5025例患者共16680.4人年暴露,平均随访约3年,未发现新的安全性信号。
- 观察淋巴瘤率0.060事件/100人年,低于估算背景率0.084事件/100人年。
- 单侧95%CI上限0.102事件/100人年低于背景率两倍0.168事件/100人年,达到排除风险加倍目标。
核心结论
- PYRAMID是常规临床实践中随访时间最长的阿达木单抗前瞻性研究,长达6年。
- 未报告新的安全性信号。
- 预设的排除阿达木单抗淋巴瘤风险加倍的研究目标已达成。
研究设计与样本
- PYRAMID为前瞻性、真实世界、长期注册研究,旨在排除阿达木单抗治疗克罗恩病患者淋巴瘤风险加倍。
- 纳入按当地产品标签新处方或正在接受阿达木单抗的中重度活动性克罗恩病患者,随访长达6年并分析不良事件。
- 共评估5025例患者,阿达木单抗注册暴露16680.4人年,平均随访约3年/患者。
- 将注册研究暴露校正的观察淋巴瘤率与来自监测、流行病学和最终结果17注册数据库的性别匹配一般人群估算背景淋巴瘤率比较,并按克罗恩病人群预期既往或合并硫嘌呤使用进行调整。
主要发现
- 治疗中出现严重不良事件4129例次(n=1853[36.9%];24.8事件/100人年)。
- 严重感染792例次(n=556[11.1%];4.7事件/100人年)。
- 恶性肿瘤134例次(n=116[2.3%];0.8事件/100人年),包括10例淋巴瘤。
- 观察淋巴瘤率0.060事件/100人年,低于估算背景率0.084事件/100人年。
- 观察淋巴瘤率单侧95%CI上限0.102事件/100人年,低于估算背景率两倍0.168事件/100人年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Real-world, prospective, long-term studies in Crohn's disease (CD) characterizing adalimumab safety data and lymphoma risk were lacking. We present the final results from the PYRAMID registry, which was designed to rule out a doubling of lymphoma risk in adalimumab-treated patients with CD. METHODS: Patients with moderately to severely active CD newly prescribed or currently receiving adalimumab according to local product labels were followed for up to 6 years and analyzed for adverse events (AEs). The registry exposure-adjusted observed rate of lymphoma was compared with the estimated background lymphoma rate from a sex-matched general population in the Surveillance, Epidemiology, and End Results 17 Registry database adjusted for anticipated prior or concurrent thiopurine use in a CD population. RESULTS: A total of 5025 patients were evaluated (16680.4 PY of adalimumab registry exposure, ≈3 years/patient mean follow-up). Registry treatment-emergent AEs included 4129 serious AEs (n = 1853 [36.9%]; 24.8 E/100 PY), 792 serious infections (n = 556 [11.1%]; 4.7 E/100 PY), and 134 malignancies (n = 116 [2.3%]; 0.8 E/100 PY), including ten lymphomas. The observed lymphoma rate (0.060 E/100 PY) was lower than the estimated background rate (0.084 E/100 PY), and the upper bound of the one-sided 95% CI of the observed rate (0.102 E/100 PY) was lower than double the estimated rate (0.168 E/100 PY). CONCLUSIONS: PYRAMID is the longest prospective adalimumab study in routine clinical practice, with up to 6 years of follow-up. No new safety signals were reported. The pre-specified registry objective of ruling out a doubling of lymphoma risk with adalimumab was met.
引用
- DʼHaens G, Reinisch W, Panaccione R, et al. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am J Gastroenterol. 2018. PMID: 29867173. doi:10.1038/s41395-018-0098-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。